U.S. Biologic, Inc – Trademark Portfolio
Entity Type: 03
U.S. Biologic, Inc holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ZOOHUB, ORISBIO, and GUIDING DISEASE PREVENTION. The owner is based in Memphis, TN.
3 North Dunlap st
VAN VLEET BUILDING
Memphis, TN 38103
Showing of trademarks Trademarks
Trademark Classifications
U.S. Biologic, Inc's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does U.S. Biologic, Inc have?
U.S. Biologic, Inc has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 8 abandoned.
What trademark classes does U.S. Biologic, Inc file in?
U.S. Biologic, Inc files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are U.S. Biologic, Inc's most well-known trademarks?
U.S. Biologic, Inc's registered trademark portfolio includes well-known marks such as ZOOHUB, ORISBIO, and GUIDING DISEASE PREVENTION. These are among 3 currently registered trademarks in the portfolio.
What is U.S. Biologic, Inc's trademark registration success rate?
U.S. Biologic, Inc has a 27% trademark registration rate, with 3 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.